

Vitamin C may alleviate exercise-induced bronchoconstriction: a meta-analysis

Harri Hemilä

To cite: Hemilä H. Vitamin C may alleviate exercise-induced bronchoconstriction: a meta-analysis. *BMJ Open* 2013;**3**:e002416. doi:10.1136/bmjopen-2012-002416

► Prepublication history and additional material for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2012-002416>).

Received 27 November 2012
Revised 16 May 2013
Accepted 17 May 2013

This final article is available for use under the terms of the Creative Commons Attribution Non-Commercial 2.0 Licence; see <http://bmjopen.bmj.com>

Department of Public Health, University of Helsinki, Helsinki, Finland

Correspondence to

Dr Harri Hemilä;
harri.hemila@helsinki.fi

ABSTRACT

Objective: To determine whether vitamin C administration influences exercise-induced bronchoconstriction (EIB).

Design: Systematic review and meta-analysis.

Methods: MEDLINE and Scopus were searched for placebo-controlled trials on vitamin C and EIB. The primary measures of vitamin C effect used in this study were: (1) the arithmetic difference and (2) the relative effect in the postexercise forced expiratory volume in 1 s (FEV₁) decline between the vitamin C and placebo periods. The relative effect of vitamin C administration on FEV₁ was analysed by using linear modelling for two studies that reported full or partial individual-level data. The arithmetic differences and the relative effects were pooled by the inverse variance method. A secondary measure of the vitamin C effect was the difference in the proportion of participants suffering from EIB on the vitamin C and placebo days.

Results: 3 placebo-controlled trials that studied the effect of vitamin C on EIB were identified. In all, they had 40 participants. The pooled effect estimate indicated a reduction of 8.4 percentage points (95% CI 4.6 to 12) in the postexercise FEV₁ decline when vitamin C was administered before exercise. The pooled relative effect estimate indicated a 48% reduction (95% CI 33% to 64%) in the postexercise FEV₁ decline when vitamin C was administered before exercise. One study needed imputations to include it in the meta-analyses, but it also reported that vitamin C decreased the proportion of participants who suffered from EIB by 50 percentage points (95% CI 23 to 68); this comparison did not need data imputations.

Conclusions: Given the safety and low cost of vitamin C, and the positive findings for vitamin C administration in the three EIB studies, it seems reasonable for physically active people to test vitamin C when they have respiratory symptoms such as cough associated with exercise. Further research on the effects of vitamin C on EIB is warranted.

INTRODUCTION

Exercise-induced bronchoconstriction (EIB) is a transient narrowing of the airways that occurs during or after exercise. Usually, a 10% or greater exercise-induced decline in forced expiratory volume in 1 s (FEV₁) is classified as EIB.¹ The prevalence of EIB varies

ARTICLE SUMMARY

Article focus

- Exercise causes airway narrowing in about 10% of the general population and in up to 50% of competitive athletes.
- Laboratory studies have indicated that vitamin C may have an alleviating influence on bronchoconstriction.
- The aim of this research was to examine whether vitamin C administration influences forced expiratory volume in 1 s (FEV₁) decline caused by exercise.

Key messages

- Vitamin C may alleviate respiratory symptoms caused by exercise.
- In future studies, linear modelling should be used to examine the effect of vitamin C on the postexercise FEV₁ decline instead of calculating the mean effect of vitamin C on the postexercise FEV₁ decline.

Strengths and limitations of this study

- The included studies were methodologically satisfactory and their results were consistent and close.
- The included studies were small with 40 participants in all.

from about 10% in the general population to about 50% in some fields of competitive athletics.¹ The pathophysiology of EIB is not well understood. However, respiratory water loss leads to the release of inflammatory mediators, such as histamine, leukotrienes (LTs) and prostaglandins (PGs), all of which can cause bronchoconstriction.^{1 2} Increased levels of exhaled nitric oxide have also been associated with EIB.³

There is evidence that vitamin C plays a role in lung function. The production of various prostanoids in lung tissues is influenced by vitamin C, and vitamin C deficiency increases the level of bronchoconstrictor PGF_{2α}.⁴⁻⁶ An increase in airway hyper-responsiveness to histamine, which was further enhanced by indomethacin administration, was observed in guinea pigs on a diet deficient in vitamin C.⁶ In isolated guinea

pig trachea smooth muscle, vitamin C decreased the contractions caused by $\text{PGF}_{2\alpha}$, histamine and carbamylcholine.^{4 7 8} Indomethacin antagonised the effect of vitamin C on chemically induced bronchoconstriction in humans^{9 10} and the effect of vitamin C on the contractions of guinea pig tracheal muscle.⁸ Thus, the effects of vitamin C might be partly mediated by alterations in PG metabolism. In humans, a 2-week vitamin C (1.5 g/day) administration regime reduced the postexercise increase in the urinary markers for the bronchoconstrictors $\text{LTC}_4\text{-LTE}_4$ and PGD_2 , in addition to reducing the increase in exhaled nitric oxide.¹¹

Heavy physical exertion generates oxidative stress, and therefore, as an antioxidant, the effects of vitamin C might be more manifest in people doing exercise.^{12 13} The importance of vitamin C on the respiratory system is also indicated by the decrease in the incidence of the common cold in people under heavy acute physical stress^{14 15} and by its effects on the severity of the upper and lower respiratory tract infections.¹⁵⁻¹⁷

Previously, a systematic review examined the effect of vitamin C on EIB.¹⁸ However, there were substantial errors in the extraction of data and data analysis in that review.¹⁹ The purpose of this systematic review is to examine whether vitamin C administration influences the postexercise FEV_1 decline.

METHODS

Types of studies

Controlled trials, both randomised and non-randomised, were included in this systematic review. Only placebo-controlled blinded trials were included as the severity of EIB might be affected by the patients' awareness of the treatment. Studies that used children and adults of either gender and any age were considered eligible.

Types of interventions

The intervention considered was oral or intravenous administration of vitamin C (ascorbic acid or its salts) of at least 0.2 g daily for a single day or for a more extended period. The dose limit was set as a pragmatic choice. When a trial with a low dose gives a negative result, the negative findings can be attributed to that low dosage. Thus, trials with large doses are more critical for testing whether vitamin C is effective in influencing EIB.

The outcomes and the measure of the vitamin C effect

The primary outcome in this meta-analysis is the relative FEV_1 decline caused by exercise (as a percentage). The measures selected for the vitamin C effect were: (1) the arithmetic difference in the postexercise decline of FEV_1 between the placebo and vitamin C periods; this is called the percentage point difference and (2) the relative effect in the decline of postexercise FEV_1 between the vitamin C and placebo periods. A secondary outcome in this meta-analysis was the proportion of participants who suffered from EIB after the exercise test,

and the measure of vitamin C effect was taken as the difference in the occurrence in EIB between the vitamin C and placebo days.

Literature searches

MEDLINE (OVID) was searched using the Medical Subject Headings (MeSH) terms 'ascorbic acid' and 'exercise-induced asthma'. A similar search was carried out in Scopus. No language restrictions were used. The databases were searched from their inception to February 2013. The reference lists of identified studies and review articles were screened for additional references. See online supplementary file 1 for the flow diagram of the literature search.

Selection of studies and data extraction

Five controlled trials that report on vitamin C and EIB were identified. Three of them satisfied the selection criteria (table 1). One of the studies that was not included was not placebo controlled²² and the other studied the combination of vitamins C and E.²³ The data of the three included trials were extracted and analysed. The original study authors were contacted when appropriate in order to obtain further data.

Schachter and Schlesinger²⁰ reported the individual-level FEV_1 measurements for a 12-participant crossover study. The decline in FEV_1 caused by exercise was calculated in this present study (see online supplementary file 2).

Tecklenburg *et al*¹¹ reported the mean decline in post-exercise FEV_1 for the vitamin C and placebo phases of an eight-participant crossover study. However, these authors did not report the paired SD value for the mean difference between the two phases. Dr Tecklenburg was subsequently contacted, and she kindly sent the paired SD value for the mean difference in decline of the post-exercise FEV_1 (see online supplementary file 2).

Cohen *et al*²¹ reported FEV_1 values before and after exercise in only 11 of the 20 participants of a crossover study. These 11 had been selected because of the disappearance of EIB during the study. Thus, the difference in the postexercise FEV_1 decline between the vitamin C and placebo days can be calculated for these 11 participants (the mean vitamin C effect was a reduction of 20.4 percentage points in the postexercise decline in FEV_1). Dr Cohen was contacted, but he no longer retained those data. Therefore, to include the Cohen *et al* trial in this meta-analysis, the FEV_1 values for the remaining nine participants had to be imputed. A conservative 'no vitamin C effect' estimate was imputed for all the nine participants with missing data (see online supplementary file 2). As a sensitivity analysis, the Cohen *et al* study was excluded from the meta-analysis in figure 1 to examine whether its exclusion influenced the conclusions.

Cohen *et al* also reported the number of participants who suffered from EIB after the exercise test. This outcome did not require imputations and it was used as a secondary outcome for comparing the vitamin C and placebo days in the Cohen study.

Table 1 Trials on vitamin C supplementation and exercise-induced bronchoconstriction

Study		Descriptions
Schachter and Schlesinger ²⁰	Methods	Randomised, double-blind, placebo-controlled crossover trial
	Participants	12 asthmatic participants, selected from among workers of Yale University in the USA: "all 12 participants gave a characteristic description of EIB." All included participants had at least 20% reduction in maximal expiratory flow 40% after exercise 5 Males, 7 females; mean age of 26 years (SD 5 years)
	Type of exercise	Exercise by using a cycloergometer was begun at a constant speed of 20 km/h against a zero workload. At the end of each 1 min interval, the workload was increased by 150 kpm/min, keeping the pedalling speed constant throughout the experiment. Exercise against progressively larger workloads was continued until either the heart rate reached 170 bpm or the participants fatigued
	Intervention	On 2 subsequent days, the participants ingested 0.5 g of vitamin C or sucrose placebo in identical capsules 1.5 h before the exercise. Washout overnight
Cohen <i>et al</i> ²¹	Outcome Notes	Change in FEV ₁ was calculated as: (preexercise vs 5 min postexercise) See online supplementary file 2 for the calculation of the vitamin C effect from the individual-level data
	Methods	Randomised, double-blind, placebo-controlled crossover trial
	Participants	20 asthmatic participants in Israel. All of them had demonstrated EIB by having a 'decline of at least 15%' in FEV ₁ after a standard exercise test 13 Males, 7 females; mean age of 14 years (range 7–28 years)
	Type of exercise	A 7 min exercise session using a motorised treadmill. Each participant exercised to submaximal effort at a speed and slope to provide 80% of the motional oxygen consumption as adjudged by a pulse oximeter
Tecklenburg <i>et al</i> ¹¹	Intervention Outcomes	2 g of vitamin C or placebo 1 h before the exercise. Washout 1 week Change in FEV ₁ was calculated as: (preexercise vs 8 min postexercise). Secondary outcome: proportion of participants who suffered from EIB after the exercise session (decline in FEV ₁ at least 15%)
	Notes	Individual-level data on the FEV ₁ levels was reported only for 11 of the 20 participants (Cohen <i>et al</i> , table 2). Dr Cohen was contacted, but he no longer had the data. Therefore, a conservative 'no vitamin C effect' was imputed for the 9 participants for whom experimental data were not available; see online supplementary file 2
	Methods	Randomised, double-blind, placebo-controlled crossover trial
Tecklenburg <i>et al</i> ¹¹	Participants	8 participants from a population of university students and the local community, Indiana, USA, with physician-diagnosed mild-to-moderate asthma. All participants had documented EIB as indicated by a 'drop greater than 10%' in postexercise FEV ₁ . They also had a history of chest tightness, shortness of breath and intermittent wheezing following exercise. 2 Males, 6 females; mean age of 24.5 years (SD 5 years)
	Type of exercise	Participants ran on a motorised treadmill, elevated by 1% per min until 85% of the age-predicted maximum heart rate and ventilation exceeding 40–60% of the predicted maximum voluntary ventilation. Participants maintained this exercise intensity for 6 min. Following the 6 min steady state exercise, the grade of the treadmill continued to increase at 1% per min until volitional exhaustion
	Intervention	1.5 g vitamin C or sucrose placebo was administered as capsules matched for colour and size daily for 2 weeks. Washout 1 week. Participants were advised to avoid high vitamin C foods during the study
	Outcome	Change in FEV ₁ was calculated as: (preexercise vs the lowest value within 30 min postexercise)
	Notes	Dr Tecklenburg kindly made the mean and SD for the paired FEV ₁ decline available. For the decline in FEV ₁ level, the mean difference was +6.5 percentage points (paired SD 7.4) in favour of vitamin C

EIB, exercise-induced bronchoconstriction; FEV₁, forced expiratory volume in 1 s.

Statistical analysis

The statistical heterogeneity of the three studies was assessed by using the χ^2 test and the I² index.²⁴ The

latter examines the percentage of total variation across studies that is due to heterogeneity between studies rather than by randomness. A value of I² greater than




Figure 1 Percentage point effect of vitamin C on the decline in FEV₁ caused by exercise. The horizontal lines indicate the 95% CI for the three trials and the squares in the middle of the lines indicate the mean effect of the study. The diamond shape at the bottom indicates the 95% CI for the pooled effect. FEV₁, forced expiratory volume in 1 s; seTE, SE of TE; TE, treatment effect; W, weight of the study.

about 70% indicates a high level of heterogeneity. Since the three identified trials showed no statistical heterogeneity, their results were pooled using the inverse variance method assuming a fixed effect by running the program ‘metagen’ of the R package (see online supplementary file 2 for details of the calculations).²⁵ The program ‘forest.meta’ of the R package was used to construct the forest plots.

To examine the relative effect of vitamin C on the post-exercise FEV₁ decline, the vitamin C effect was modelled using the placebo-day postexercise FEV₁ decline as the explanatory variable, by using the linear model ‘lm’ program of the R package.²⁵ To test whether the addition of the placebo-day postexercise FEV₁ decline values significantly improves the linear model fit, the model containing the placebo-day FEV₁ decline values was compared with the model without them. The improvement of the model fit was calculated from the change in $-2 \times \log$ (likelihood), which follows the χ^2 (1 df) distribution.

To study the effect of vitamin C on the proportion of participants who suffered from EIB in the Cohen *et al* study, the mid p value was calculated²⁶ and the 95% CI was calculated by using the Agresti-Caffo method.²⁷

The two-tailed p values are presented in this text.

RESULTS

Three randomised, placebo-controlled, double-blind cross-over trials that had examined the effect of vitamin C supplementation on the decline in FEV₁ caused by exercise were retrieved. Double-blind means that all studies used allocation concealment, although the term was not used. The experimental conditions were similar (table 1). The three trials had a total of 40 participants. There was no statistical heterogeneity found between the three studies for the percentage points scale: $I^2=0\%$; χ^2 (2 df)=1.1; p=0.5. Therefore, the pooled percentage point estimate of the vitamin C effect was calculated (figure 1). Compared with the placebo phases, the mean reduction in the postexercise FEV₁ decline was 8.4 percentage points during the vitamin C phases (95% CI 4.6 to 12.2; p<0.001).

In the Schachter and Schlesinger²⁰ study, the postexercise FEV₁ decline was 17.6% for placebo, but only 10.2% for vitamin C (0.5 g single dose), with a 7.4 percentage point (95% CI -0.1 to 14.9; p=0.054) improvement for the vitamin C treatment. In the Tecklenburg *et al*¹¹ study, the postexercise FEV₁ decline was 12.9% when on placebo, but only 6.4% when on vitamin C (1.5 g/day for 2 weeks), indicating an improvement of 6.5 percentage points (95% CI 0.3 to 12.7; p=0.042) for vitamin C. With the conservative imputation of the ‘no vitamin C effect’ for nine participants in the Cohen *et al*²¹ study, there was a reduction in the postexercise FEV₁ decline by 11.2 percentage points (95% CI 4.8 to 17.6; p=0.002) on the vitamin C day (2 g single dose).

EIB is not a dichotomous condition; instead, there is a continuous variation in the possible level of FEV₁ decline caused by exercise. A single constant percentage point estimate of the vitamin C effect for all people who suffer from EIB may thus be simplistic. Instead, it is possible that a relative scale would better capture the effect of vitamin C. Schachter and Schlesinger²⁰ published individual-level data for all their 12 participants, and thus their data were analysed using linear modelling to examine whether the vitamin C effect might depend on the placebo-day postexercise FEV₁ decline, that is, on the baseline severity of EIB (figure 2). Adding the placebo-day postexercise FEV₁ decline values to the null linear model, which is equivalent to the t test, improved the model fit by χ^2 (1 df)=16.5, corresponding to p<0.001. This indicates that the linear model that includes the placebo-day postexercise FEV₁ decline explains the effect of vitamin C much better than the constant 7.4 percentage point effect for all their participants suffering from EIB. The slope of the linear model indicates a 55% reduction in the decline of the postexercise FEV₁ (95% CI 32% to 78%; p<0.001) for vitamin C administration compared with placebo. Thus, in the percentage points scale, though there was a trend towards a mean vitamin C effect, the difference between vitamin C and placebo in the Schachter and Schlesinger trial was not significant (p=0.054), whereas in the linear model




Figure 2 The effect of vitamin C on postexercise forced expiratory volume in 1 s (FEV₁) decline as a function of the placebo-day postexercise FEV₁ decline for the Schachter and Schlesinger study.²⁰ The squares show the 12 participants of the study. The vertical axis shows the difference in postexercise FEV₁ decline between the vitamin C and the placebo days. The horizontal axis shows the postexercise FEV₁ decline on the placebo day. The black line indicates the fitted linear regression line. The horizontal dash (-) line indicates the level of identity between vitamin C and placebo. See online supplementary file 2 for the calculations.




Figure 3 The effect of vitamin C on postexercise forced expiratory volume in 1 s (FEV₁) decline as a function of the placebo-day postexercise FEV₁ decline for the Cohen *et al*²¹ study. The filled squares show the 11 participants for whom data were reported and the empty squares show the nine participants for whom the conservative ‘no vitamin C effect’ data were imputed. The vertical axis shows the difference in the postexercise FEV₁ decline between the vitamin C and the placebo days. The horizontal axis shows the postexercise FEV₁ decline on the placebo day. The black line indicates the fitted linear regression line. The horizontal dash (-) line indicates the level of identity between vitamin C and placebo. The linear regression line was fitted through the origin, since the variation in the placebo-day FEV₁ decline values is narrow. See online supplementary file 2 for the calculations.

the slope indicates a highly significant difference between vitamin C and placebo ($p < 0.001$).

Cohen *et al*²¹ published individual-level data for only 11 of their 20 participants (filled squares in figure 3). A conservative ‘no vitamin C effect’ was imputed for the remaining nine participants (open squares in figure 3). Only those participants who had a decline in postexercise FEV₁ of at least 15% were included in the Cohen *et al* study, and therefore the horizontal variation in the Cohen *et al* data was narrow. Fitting the linear regression line through the origin indicates a 42% reduction in the postexercise FEV₁ decline (95% CI 19% to 64%) with vitamin C administration.

Tecklenburg *et al*¹¹ did not report individual-level data for their eight participants and the data were not available. The mean values indicate a 50.4% (95% CI 2.4% to 98%) reduction in the postexercise FEV₁ decline for the vitamin C period.

There was no statistical heterogeneity found between the three studies on the relative effect scale: $I^2 = 0\%$; χ^2 (2 df) = 0.7; $p = 0.7$. Therefore, the pooled estimate of the relative vitamin C effect was calculated for the three trials (figure 4). Compared with the placebo phases, vitamin C administration reduced the postexercise FEV₁ decline by 48% (95% CI 33% to 64%; $p < 0.001$).

As a sensitivity test, the Cohen *et al* study was excluded from the meta-analysis in figure 1. On the basis of the

two remaining trials, the estimate of the vitamin C effect on the postexercise FEV₁ decline became 6.8 percentage points (95% CI 2.0 to 11.6; $p = 0.005$). Thus, the Cohen *et al* study imputations are not crucial for the conclusion that vitamin C influences the postexercise FEV₁ decline.

Finally, although Cohen *et al* did not report individual-level data for the postexercise FEV₁ decline values for nine of their participants, they reported the presence or absence of EIB (at least a 15% decline in postexercise FEV₁) on the vitamin C and placebo days and this dichotomised FEV₁ outcome does not suffer from missing data. On the placebo day, 100% (20/20) of participants suffered from EIB, whereas on the vitamin C day, only 50% (10/20) suffered from EIB. This outcome gives a 50 percentage point decrease (95% CI 23 to 68; $p < 0.001$) in the occurrence of EIB following vitamin C administration.

DISCUSSION

In this meta-analysis of three randomised placebo-controlled double-blind trials, vitamin C was found to reduce the postexercise decline in FEV₁ by a mean of 8.4 percentage points (figure 1). Nevertheless, there is a




Figure 4 Relative effect of vitamin C on the decline in FEV₁ caused by exercise. The horizontal lines indicate the 95% CI for the three trials and the squares in the middle of the lines indicate the mean effect of the study. The diamond shape at the bottom indicates the 95% CI for the pooled effect. The estimates for the Schachter 1982 and Cohen 1997 studies are based on the slopes of the linear models in figures 3 and 4. The estimates for the Tecklenburg 2007 study are the study mean estimates. FEV₁, forced expiratory volume in 1 s; seTE, SE of TE; TE, treatment effect; W, weight of the study.

great variation in the level of FEV₁ decline caused by exercise. Therefore, it may not be reasonable to assume that a single and constant percentage point estimate of the vitamin C effect is valid for all persons suffering from EIB. Linear modelling of the Schachter and Schlesinger²⁰ data indicated that it is much better to study the response to vitamin C administration as a relative effect (figure 2). However, full individual-level data were not available for the other two trials. Nonetheless, all three studies are consistent with vitamin C administration halving the postexercise decline in FEV₁ (figure 4).

The Cohen *et al*²¹ study required imputations for nine participants; however, excluding the Cohen *et al* study from the percentage point meta-analysis did not influence conclusions. Furthermore, Cohen *et al* reported that the number of participants who suffered from EIB dropped from 100% on the placebo day to 50% on the vitamin C day and this outcome did not require imputations; yet the highly significant benefit of vitamin C was also seen in this outcome.

The three studies included in this systematic review indicate that 0.5–2 g of vitamin C administration before exercise may have a beneficial effect on many people suffering from EIB. All the three trials were double-blind placebo-controlled randomised trials. The total number of participants in the three trials is only 40. However, the three trials were carried out in three different decades and on two different continents. The criteria for EIB differed and the mean age of the participants was 14 years in the Cohen *et al* study but 25 and 26 years in the two other studies. Still, all the studies found a 50% reduction in the postexercise FEV₁ decline. It is not evident how far this 50% estimate can be generalised, but the close estimate in such different studies suggests that the estimate may also be valid for several other people who suffer from EIB.

The search, screening and selection for trials and data extraction were carried out by one person, which may be considered a limitation of this study. In addition, only

two databases were searched; however, in an independent literature search, the Cochrane review on vitamin C and asthma did not identify more trials on vitamin C and EIB.¹⁸ Data analysis was also performed by one person, but the supplementary files show the extracted data and data analyses, which makes the study transparent. No risk of bias or quality assessment was performed as part of this study.

In evidence-based medicine, the primary question is whether an intervention has effects on clinically relevant outcomes, as well as on symptoms such as coughs. With such a perspective, the aetiology of respiratory symptoms is not of prime importance. Given the low cost and safety of vitamin C,^{15 28} and the consistency of positive findings in the three studies on EIB, it seems reasonable for physically fit and active people to test vitamin C on an individual basis if they have respiratory symptoms such as cough associated with exercise.

The promising results of EIB and common cold studies indicate that further research on vitamin C and the respiratory symptoms of physically active people are warranted. In future trials, statistical modelling should be used to examine the effect of vitamin C on FEV₁ levels, instead of simply calculating the percentage point estimates. Although the primary question in the evidence-based medicine framework is to assess the effectiveness of vitamin C on clinically relevant outcomes, the aetiology of the respiratory symptoms should also be investigated in future investigations.

Acknowledgements The author would like to thank Dr Tecklenburg who kindly supplied supplementary data for this analysis and Elizabeth Stovold for her contributions to an early version of this manuscript, by helping in the literature searches, considering studies for inclusion and extracting data for the meta-analysis.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement All collected and imputed data are presented in online supplementary files 2 and 3 and are freely available.


REFERENCES

1. Weiler JM, Anderson SD, Randolph C. Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction. *Ann Allergy Asthma Immunol* 2010;105(6 Suppl):S1–47.
2. Anderson SD, Kippelen P. Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes. *J Allergy Clin Immunol* 2008;122:225–35.
3. Buchvald F, Hermansen MN, Nielsen KG, et al. Exhaled nitric oxide predicts exercise-induced bronchoconstriction in asthmatic school children. *Chest* 2005;128:1964–7.
4. Puglisi L, Berti F, Bosisio E, et al. Ascorbic acid and PGF2 α antagonism on tracheal smooth muscle. *Adv Prostaglandin Thromboxane Res* 1976;1:503–6.
5. Rothberg KG, Hitchcock M. Effects of ascorbic acid deficiency on the in vitro biosynthesis of cyclooxygenase metabolites in guinea pig lungs. *Prostaglandins Leukot Med* 1983;12:137–47.
6. Mohsenin V, Tremml PG, Rothberg KG, et al. Airway responsiveness and prostaglandin generation in scorbutic guinea pigs. *Prostaglandins Leukot Essent Fatty Acids* 1988;33:149–55.
7. Zuskin E, Lewis AJ, Bouhuys A. Inhibition of histamine-induced airway constriction by ascorbic acid. *J Allergy Clin Immunol* 1973;51:218–26.
8. Sipahi E, Ercan ZS. The mechanism of the relaxing effect of ascorbic acid in guinea pig isolated tracheal muscle. *Gen Pharmacol* 1997;28:757–60.
9. Ogilvy CS, DuBois AB, Douglas JS. Effects of ascorbic acid and indomethacin on the airways of healthy male subjects with and without induced bronchoconstriction. *J Allergy Clin Immunol* 1981;67:363–9.
10. Mohsenin V, Dubois AB, Douglas JS. Effect of ascorbic acid on response to methacholine challenge in asthmatic subjects. *Am Rev Respir Dis* 1983;127:143–7.
11. Tecklenburg SL, Mickleborough TD, Fly AD, et al. Ascorbic acid supplementation attenuates exercise-induced bronchoconstriction in patients with asthma. *Respir Med* 2007;101:1770–8.
12. Powers SK, Jackson MJ. Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. *Physiol Rev* 2008;88:1243–76.
13. Ashton T, Young IS, Peters JR, et al. Electron spin resonance spectroscopy, exercise, and oxidative stress: an ascorbic acid intervention study. *J Appl Physiol* 1999;87:2032–6. <http://www.ncbi.nlm.nih.gov/pubmed/10601146>
14. Hemilä H. Vitamin C and common cold incidence: a review of studies with subjects under heavy physical stress. *Int J Sports Med* 1996;17:379–83. <http://hdl.handle.net/10250/7983> (accessed 7 May 2013)
15. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. *Cochrane Database Syst Rev* 2013;(1):CD000980.
16. Hemilä H. Vitamin C supplementation and common cold symptoms: problems with inaccurate reviews. *Nutrition* 1996;12:804–9. <http://hdl.handle.net/10250/7979> (accessed 7 May 2013)
17. Hemilä H, Louhiala P. Vitamin C may affect lung infections. *J R Soc Med* 2007;100:495–8.
18. Kaur B, Rowe BH, Stovold E. Vitamin C supplementation for asthma. *Cochrane Database Syst Rev* 2009;(1):CD000993.
19. Hemilä H. Feedback. In: Kaur B, Rowe BH, Stovold E. Vitamin C supplementation for asthma. *Cochrane Database Syst Rev* 2009;(1):CD000993. <http://hdl.handle.net/10138/38500> (accessed 7 May 2013)
20. Schachter EN, Schlesinger A. The attenuation of exercise-induced bronchospasm by ascorbic acid. *Ann Allergy* 1982;49:146–51. <http://www.ncbi.nlm.nih.gov/pubmed/7114587>
21. Cohen HA, Neuman I, Nahum H. Blocking effect of vitamin C in exercise-induced asthma. *Arch Pediatr Adolesc Med* 1997;151:367–70.
22. Miric M, Haxhiu MA. Effect of vitamin C on exercise-induced bronchoconstriction [Serbo-Croatian]. *Plucne Bolesti* 1991;43:94–7. <http://www.ncbi.nlm.nih.gov/pubmed/1766998>
23. Murphy JD, Ferguson CS, Brown KR, et al. The effect of dietary antioxidants on lung function in exercise induced asthma [abstract]. *Med Sci Sports Exerc* 2002;34(5 Suppl):S155.
24. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analysis. *BMJ* 2003;327:557–60.
25. The R Project for Statistical Computing. <http://www.r-project.org/> (accessed 7 May 2013)
26. Lydersen S, Fagerland MW, Laake P. Recommended tests for association in 2 \times 2 tables. *Stat Med* 2009;28:1159–75. <http://www.ncbi.nlm.nih.gov/pubmed/19170020>
27. Fagerland MW, Lydersen S, Laake P. Recommended confidence intervals for two independent binomial proportions. *Stat Methods Med Res* 2011. Published Online First 2011. doi:10.1177/0962280211415469
28. Hathcock JN, Azzi A, Blumberg J, et al. Vitamins E and C are safe across a broad range of intakes. *Am J Clin Nutr* 2005;81:736–45.

Supplementary file 1

Vitamin C may alleviate exercise-induced bronchoconstriction: a meta-analysis
Harri Hemilä

Flow diagram of the literature search 12 Feb 2013



Supplementary file 3

Vitamin C may alleviate exercise-induced bronchoconstriction: a meta-analysis

R-program printouts (3 March 2013)

Harri Hemilä
Department of Public Health
University of Helsinki
Helsinki
Finland
harri.hemila@helsinki.fi
<http://www.mv.helsinki.fi/home/hemila/>

Contents

Page

- 2 **Schachter**
Data and the linear model with only the intercept (t-test)
Calculation of the variables is shown in supplementary file 2
- 3 **Schachter**
Linear model with placebo-day FEV1 decline as the added explanatory variable
Log likelihood test for comparing the two models for the Schachter data
- 4 **Cohen**
Data and the linear model
Calculation of the variables is shown in supplementary file 2
- 5 **Fig 1** meta-analysis and sensitivity analysis in which Cohen is excluded
- 6 **Fig 4** meta-analysis

```
> Schachter
  PL_FEV1_Diff VitC_Effect
1      -10.71         3.57
2      -25.00        11.67
3      -36.36        16.36
4      -37.50        32.74
5         0.00         0.00
6         0.00       -11.11
7         0.00        -4.35
8        -4.76         4.76
9       -14.81         6.81
10         2.38        -2.38
11       -51.85        18.52
12       -32.00        12.00
```

```
> LinearModel.10 <- lm(VitC_Effect ~ 1, data=Schachter)
```

```
> summary(LinearModel.10)
```

```
Call:
lm(formula = VitC_Effect ~ 1, data = Schachter)
```

```
Residuals:
    Min       1Q   Median       3Q      Max
-18.492  -7.978  -1.597   5.707  25.358
```

```
Coefficients:
            Estimate Std. Error t value Pr(>|t|)
(Intercept)    7.383     3.414   2.162  0.0535
---
```

```
Residual standard error: 11.83 on 11 degrees of freedom
```

```
> confint(LinearModel.10)
                2.5 %    97.5 %
(Intercept) -0.1316784 14.89668
```

```
> LinearModel.11 <- lm(VitC_Effect ~ 1 + PL_FEV1_Diff, data=Schachter)
```

```
> summary(LinearModel.11)
```

```
Call:
```

```
lm(formula = VitC_Effect ~ 1 + PL_FEV1_Diff, data = Schachter)
```

```
Residuals:
```

Min	1Q	Median	3Q	Max
-8.7513	-2.3440	0.0687	1.5644	14.2852

```
Coefficients:
```

	Estimate	Std. Error	t value	Pr(> t)
(Intercept)	-2.3587	2.5400	-0.929	0.374966
PL_FEV1_Diff	-0.5550	0.1021	-5.437	0.000286

Residual standard error: 6.237 on 10 degrees of freedom
Multiple R-squared: 0.7472, Adjusted R-squared: 0.7219
F-statistic: 29.56 on 1 and 10 DF, p-value: 0.0002862

```
> confint(LinearModel.11)
```

	2.5 %	97.5 %
(Intercept)	-8.0182460	3.3008733
PL_FEV1_Diff	-0.7825026	-0.3275514

```
> lrtest(LinearModel.10,LinearModel.11)
```

```
Likelihood ratio test
```

```
Model 1: VitC_Effect ~ 1
```

```
Model 2: VitC_Effect ~ 1 + PL_FEV1_Diff
```

	#Df	LogLik	Df	Chisq	Pr(>Chisq)
1	2	-46.149			
2	3	-37.899	1	16.502	4.861e-05

```

> CohenPubImp
  PL_FEV1_Diff VitC_Effect
1      -26.45      16.39
2      -50.00      44.90
3      -33.33      28.12
4      -27.18      18.51
5      -21.31      17.91
6      -14.58       8.29
7      -19.22      19.22
8      -21.90      38.21
9      -20.00      15.83
10     -25.13      10.32
11     -18.67       6.49
12     -40.60       0.00
13     -36.30       0.00
14     -33.30       0.00
15     -30.70       0.00
16     -28.20       0.00
17     -25.80       0.00
18     -23.20       0.00
19     -20.10       0.00
20     -15.90       0.00

```

```

> LinearModel.21 <- lm(VitC_Effect ~ 0 + PL_FEV1_Diff, data=CohenPubImp)

```

```

> summary(LinearModel.21)

```

Call:

```
lm(formula = VitC_Effect ~ 0 + PL_FEV1_Diff, data = CohenPubImp)
```

Residuals:

	Min	1Q	Median	3Q	Max
	-16.9609	-11.0288	-0.7439	7.8580	29.0611

Coefficients:

	Estimate	Std. Error	t value	Pr(> t)
PL_FEV1_Diff	-0.4178	0.1056	-3.955	0.000849

Residual standard error: 13.2 on 19 degrees of freedom

Multiple R-squared: 0.4516, Adjusted R-squared: 0.4227

F-statistic: 15.64 on 1 and 19 DF, p-value: 0.0008485

```

> confint(LinearModel.21)

```

	2.5 %	97.5 %
PL_FEV1_Diff	-0.6388209	-0.1966937

```

> Fig_1
  Mean  SE      Study
1  6.50 3.16 Tecklenburg 2007
2  7.38 3.83  Schachter 1982
3 11.20 3.24      Cohen 1997

> meta1<-metagen(Fig_1$Mean, Fig_1$SE, Fig_1$Study)

> meta1
              95%-CI %W(fixed)
Tecklenburg 2007  6.50 [ 0.3065; 12.6935] 37.99
Schachter 1982   7.38 [-0.1267; 14.8867] 25.86
Cohen 1997      11.20 [ 4.8497; 17.5503] 36.14

Number of studies combined: k=3
              95%-CI      z  p.value
Fixed effect model  8.4262 [4.6086; 12.2439] 4.326 < 0.0001

Quantifying heterogeneity:
tau^2 < 0.0001; H = 1 [1; 2.38]; I^2 = 0% [0%; 82.4%]

Test of heterogeneity:
  Q d.f.  p.value
  1.18   2   0.5546

Details on meta-analytical method:
- Inverse variance method
- DerSimonian-Laird estimator for tau^2

> Fig_1_Sens
  Mean  SE      Study
1  6.50 3.16 Tecklenburg 2007
2  7.38 3.83  Schachter 1982

> meta1S<-metagen(Fig_1_Sens$Mean, Fig_1_Sens$SE, Fig_1_Sens$Study)

> meta1S
              95%-CI %W(fixed)
Tecklenburg 2007  6.50 [ 0.3065; 12.6935] 59.5
Schachter 1982   7.38 [-0.1267; 14.8867] 40.5

Number of studies combined: k=2
              95%-CI      z  p.value
Fixed effect model  6.8564 [2.0791; 11.6338] 2.8129 0.0049

Quantifying heterogeneity:
tau^2 < 0.0001; H = 1; I^2 = 0%

Test of heterogeneity:
  Q d.f.  p.value
  0.03   1   0.8593

Details on meta-analytical method:
- Inverse variance method
- DerSimonian-Laird estimator for tau^2

```

```

> Fig_4
  Mean    SE      Study
1 50.40 24.48 Tecklenburg 2007
2 55.50 11.61  Schachter 1982
3 41.78 11.28      Cohen 1997

> meta4<-metagen(Fig_4$Mean, Fig_4$SE, Fig_4$Study)

> meta4
                                95%-CI %W(fixed)
Tecklenburg 2007 50.40 [ 2.4201; 98.3799]      9.85
Schachter 1982  55.50 [32.7448; 78.2552]     43.78
Cohen 1997      41.78 [19.6716; 63.8884]     46.38

Number of studies combined: k=3

                                95%-CI      z  p.value
Fixed effect model  48.635 [33.5792; 63.6908] 6.3313 < 0.0001

Quantifying heterogeneity:
tau^2 < 0.0001; H = 1 [1; 1.87]; I^2 = 0% [0%; 71.3%]

Test of heterogeneity:
  Q d.f.  p.value
0.72   2   0.6962

Details on meta-analytical method:
- Inverse variance method
- DerSimonian-Laird estimator for tau^2

```